Amgen’s Amjevita US Sales On The Rise, Oncology Biosimilars Still In Slump
Amgen Reported 36% Annual Global Sales Increase For Adalimumab Biosimilar After US Launch
It seems that the first US Humira biosimilar is recovering from the predicted slow uptake, but Amgen’s oncology biosimilars portfolio continues to deteriorate.
